This morning, ATAI Life Sciences (Nasdaq: ATAI) experienced a shocking drop of nearly 40% in its stock price, plummeting to an all-time low since the company’s June 2021 Initial Public Offering. The cause? A failed lead asset from its majority-owned Perception Neuroscience unit.
If you want to invest in psychedelic stocks, ignore the hype and look at the technicals. We take a deep dive on atai Life Sciences & COMPASS Pathways
Our resident psychedelic investor explains a handful of important metrics to study when analyzing and comparing psychedelic stocks.
Psychedelic investors are about to see pivotal data presented on flagship programs by the titans of the psychedelics industry.
Our resident Psychedelic Investor James Hallifax wonders if the “Shark Tank” star’s prediction makes financial sense.
Our resident Psychedelic Investor details five companies he thinks are in strong position to win the psychedelic medicine race.
This week in psychedelic business news: Nova Mentis makes progress on autism; atai donates to MAPS; Cathie Wood eyes more psychedelic stocks.
Our resident Psychedelic Investor explains why this is an important moment for the psychedelics sector.
Friendly advice for responsibly managing speculative bets on psychedelic stocks that may rise like a phoenix or burn to the ground.
This week in psychedelic business news: A major player begins manufacturing; another rebrands; and one of the biggest gets bigger.
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.